Epigenetic modification and preliminary investigation of the mechanism of the immune evasion of HL-60 cells

Liu,Jin  Hong; Bian,Yong  Mei; Xie,Yi; Lu,Dao  Pei

doi:10.3892/mmr.2015.3526

Epigenetic modification and preliminary investigation of the mechanism of the immune evasion of HL-60 cells

Authors:
- Jin Hong Liu
- Yong Mei Bian
- Yi Xie
- Dao Pei Lu
View Affiliations

Affiliations: Department of Hematology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200240, P.R. China, Department of Pediatrics, Minhang District Maternal and Child Health Care Hospital of Shanghai, Shanghai 201102, P.R. China, Department of Hematology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
Published online on: March 20, 2015 https://doi.org/10.3892/mmr.2015.3526
Pages: 1059-1065
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to explore the effect of epigenetic modification of class II transactivator (CIITA) methylation on histocompatibility complex (MHC) class II expression and the immune evasion of leukemia HL‑60 cells. HL‑60 cells were treated with various concentrations of 5‑aza‑2'deoxycytidine (5‑Aza‑CdR) and 0.5 µmol/l suberoylanilide hydroxamic acid (SAHA) for 24 h and then stimulated by interferon γ (IFN‑γ) for 48 h. The mRNA levels of MHC class I, II and co‑stimulatory molecules were quantified by reverse transcription polymerase chain reaction (RT‑PCR). The levels of CIITA protein were determined by western blot analysis, and the CpG island methylation ratios in the CIITA promoter IV (CIITApIV) were analyzed by bisulfite‑sequencing PCR (BSP). MHC I as well as the co‑stimulatory molecules CD40 and CD80 were significantly increased following treatment with 5‑Aza‑CdR + SAHA + IFN‑γ (epigenetic groups) compared with those in the control group and IFN‑γ group (P<0.05). The expression of MHC class II and CIITA was restored and increased in an 5‑Aza‑CdR concentration‑dependent manner in the three epigenetic groups. The results of the BSP assay showed that the methylation rate of CIITApIV CpG sites decreased with the treatment of epigenetic modification and negatively correlated to the 5‑Aza‑CdR concentration. This demonstrated that the negative expression of CIITA protein was the key reason for the loss of MHC II expression in HL‑60 cells. The results of the present study may help to illustrate the mechanism of immune evasion in HL-60 cells.

View Figures

View References

1	McKenna SJ: Leukemia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 89:137–139. 2000. View Article : Google Scholar : PubMed/NCBI
2	Klippel ZK, Chou J, Towlerton AM, et al: Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC. Gene Ther. 21:337–342. 2014. View Article : Google Scholar : PubMed/NCBI
3	Siddle HV, Kreiss A, Tovar C, et al: Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer. Proc Natl Acad Sci USA. 110:5103–5108. 2013. View Article : Google Scholar : PubMed/NCBI
4	Wolkersdörfer T, Fussel M, Kiesslich T, et al: MHC class II genotype- and MHC class I and II phenotype-related parameters in sporadic colorectal cancer. Oncol Rep. 26:1165–1171. 2011.PubMed/NCBI
5	Xu WC, Li ZB, Chen YR, et al: Expression and distribution of S-100, CD83 and costimulatory molecules (CD80 and CD86) in tissues of thyroid papillary carcinoma. Cancer Invest. 29:286–292. 2011. View Article : Google Scholar : PubMed/NCBI
6	Fernando MM, Stevens CR, Walsh EC, et al: Defining the role of the MHC in autoimmunity: A review and pooled analysis. PLoS Genet. 4:e10000242008. View Article : Google Scholar : PubMed/NCBI
7	Choi NM, Majumder P and Boss JM: Regulation of major histocompatibility complex class II genes. Curr Opin Immunol. 23:81–87. 2011. View Article : Google Scholar :
8	Devaiah BN and Singer DS: CIITA and its dual roles in MHC gene transcription. Front Immunol. 4:4762013. View Article : Google Scholar
9	Otten LA, Steimle V, Bontron S and Mach B: Quantitative control of MHC class II expression by the transactivator CIITA. Eur J Immunol. 28:473–478. 1998. View Article : Google Scholar : PubMed/NCBI
10	Green MR, Yoon H and Boss JM: Epigenetic regulation during B cell differentiation controls CIITA promoter accessibility. J Immunol. 177:3865–3873. 2006. View Article : Google Scholar : PubMed/NCBI
11	Chen H, Gilbert CA, Hudson JA, Bolick SC, Wright KL and Piskurich JF: Positive regulatory domain I-binding factor 1 mediates repression of the MHC class II transactivator (CIITA) type IV promoter. Mol Immunol. 44:1461–1470. 2007. View Article : Google Scholar :
12	Pisapia L, Pozzo GD, Barba P, Citro A, Harris PE and Maffei A: Contrasting effects of IFNalpha on MHC class II expression in professional vs. nonprofessional APCs: Role of CIITA type IV promoter. Results Immunol. 2:174–183. 2012. View Article : Google Scholar
13	Baylin SB and Jones PA: A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer. 11:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
14	Sandoval J and Esteller M: Cancer epigenomics: beyond genomics. Curr Opin Genet Dev. 22:50–55. 2012. View Article : Google Scholar : PubMed/NCBI
15	Burke MJ and Bhatla T: Epigenetic modifications in pediatric acute lymphoblastic leukemia. Front Pediatr. 2:422014. View Article : Google Scholar : PubMed/NCBI
16	Chatterton Z, Burke D, Emslie KR, et al: Validation of DNA methylation biomarkers for diagnosis of acute lymphoblastic leukemia. Clin Chem. 60:995–1003. 2014. View Article : Google Scholar : PubMed/NCBI
17	Nordlund J, Backlin CL, Wahlberg P, et al: Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia. Genome Biol. 14:r1052013. View Article : Google Scholar : PubMed/NCBI
18	Savickiene J, Treigyte G, Valiuliene G, Stirblyte I and Navakauskiene R: Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells. Anticancer Drugs. 25:938–949. 2014. View Article : Google Scholar : PubMed/NCBI
19	Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 26:5541–5552. 2007. View Article : Google Scholar : PubMed/NCBI
20	Londhe P, Zhu B, Abraham J, Keller C and Davie J: CIITA is silenced by epigenetic mechanisms that prevent the recruitment of transactivating factors in rhabdomyosarcoma cells. Int J Cancer. 131:E437–E448. 2012. View Article : Google Scholar :
21	Cycon KA, Mulvaney K, Rimsza LM, Persky D and Murphy SP: Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma. Immunology. 140:259–272. 2013. View Article : Google Scholar : PubMed/NCBI
22	Candiano G, Bruschi M, Musante L, et al: Blue silver: A very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis. 25:1327–1333. 2004. View Article : Google Scholar : PubMed/NCBI
23	Dodd KW, Burns TC, Wiesner SM, et al: Transgenic mice expressing luciferase under a 4.5 kb tyrosine hydroxylase promoter. Cureus. 3:e342011.
24	Baev MV, Baev D, Radek AJ and Campbell JW: Growth of Escherichia coli MG1655 on LB medium: Monitoring utilization of sugars, alcohols, and organic acids with transcriptional micro-arrays. Appl Microbilol Biot. 71:310–316. 2006. View Article : Google Scholar
25	Cohn M: How does the immune response get started? Cell Immunol. 254:91–93. 2009. View Article : Google Scholar :
26	Weiss A, Imboden J, Hardy K, et al: The role of the T3/antigen receptor complex in T-cell activation. Annu Rev Immunol. 4:593–619. 1986. View Article : Google Scholar : PubMed/NCBI
27	Santos DO, Miranda A, Suffys P, et al: Current understanding of the dendritic cells and their co-stimulatory molecules as a key in generating efficient T cell responses in lepromatous leprosy. Curr Immunol Rev. 3:77–85. 2007. View Article : Google Scholar
28	Shafer-Weaver K, Anderson M, Malyguine A and Hurwitz AA: T cell tolerance to tumors and cancer immunotherapy. Adv Exp Med Biol. 601. pp. 357–368. 2007
29	Ueki T, Murata S, Kitamura N, Mekata E and Tani T: Pre-treatment with cyclophosphamide or OX40 (CD134) costimulation targeting regulatory T cell function enhances the anti-tumor immune effect of adoptively transferred CD8+ T cells from wild-type mice. Mol Med Rep. 2:615–620. 2009.PubMed/NCBI
30	Hung K, Hayashi R, Lafond-Walker A, et al: The central role of CD4(+) T cells in the antitumor immune response. J Exp Med. 188:2357–2368. 1998. View Article : Google Scholar : PubMed/NCBI
31	Magner WJ, Kazim AL, Stewart C, et al: Activation of MHC class I, II and CD40 gene expression by histone deacetylase inhibitors. J Immunol. 165:7017–7024. 2000. View Article : Google Scholar : PubMed/NCBI
32	Garrido C, Paco L, Romero I, et al: MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis. 33:687–693. 2012. View Article : Google Scholar : PubMed/NCBI
33	Seliger B: The link between MHC class I abnormalities of tumors, oncogenes, tumor suppressor genes and transcription factors. J Immunotoxicol. 11:308–310. 2014. View Article : Google Scholar : PubMed/NCBI
34	Daurkin I, Eruslanov E, Vieweg J and Kusmartsev S: Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2′-deoxycytidine. Cancer Immunol Immunother. 59:697–706. 2010. View Article : Google Scholar
35	Sigalotti L, Coral S, Fratta E, et al: Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy. Semin Oncol. 32:473–478. 2005. View Article : Google Scholar : PubMed/NCBI
36	Reith W, Muhlethaler-Mottet A, Masternak K, Villard J and Mach B: The molecular basis of MHC class II deficiency and transcriptional control of MHC class II gene expression. Microbes Infect. 1:839–846. 1999. View Article : Google Scholar : PubMed/NCBI
37	Ulbricht T, Alzrigat M, Horch A, et al: PMl promotes MHC class II gene expression by stabilizing the class II transactivator. J Cell Biol. 199:49–63. 2012. View Article : Google Scholar : PubMed/NCBI
38	Truax AD, Thakkar M and Greer SF: Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells. PLoS One. 7:e360132012. View Article : Google Scholar : PubMed/NCBI
39	De Lerma Barbaro A, De Ambrosis A, Banelli B, et al: Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-gamma in promyelocytic cells. Int Immunol. 20:1457–1466. 2008. View Article : Google Scholar : PubMed/NCBI
40	Radosevich M, Song Z, Gorga JC, Ksander B and Ono SJ: Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells. Invest Ophthalmol Vis Sci. 45:3185–3195. 2004. View Article : Google Scholar : PubMed/NCBI
41	Holtz R, Choi JC, Petroff MG, Piskurich JF and Murphy SP: Class II transactivator (CIITA) promoter methylation does not correlate with silencing of CIITA transcription in trophoblasts. Biol Reprod. 69:915–924. 2003. View Article : Google Scholar : PubMed/NCBI
42	Cameron EE, Bachman KE, Myohanen S, Herman JG and Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 21:103–107. 1999. View Article : Google Scholar : PubMed/NCBI
43	Shaker S, Bernstein M, Momparler LF and Momparler RL: Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk Res. 27. pp. 437–444. 2003, View Article : Google Scholar